Literature DB >> 22285549

The development of encapsulated cell technologies as therapies for neurological and sensory diseases.

M P Zanin1, L N Pettingill, A R Harvey, D F Emerich, C G Thanos, R K Shepherd.   

Abstract

Cell encapsulation therapies involve the implantation of cells that secrete a therapeutic factor to provide clinical benefits. The transplanted cells are protected from immunorejection via encapsulation in a semipermeable membrane. This treatment strategy was originally investigated as a method for protecting pancreatic islets from immunorejection, thus allowing them to secrete insulin as a chronic treatment for diabetes. Since then a significant body of work has been conducted in developing cell encapsulation therapies to treat a variety of different diseases. Many of these conditions involve neurodegeneration, such as Alzheimer's and Parkinson's disease, as cell encapsulation therapies have proven to be particularly suitable for delivering therapeutics to the central nervous system. This is mainly because they offer chronic delivery of a therapeutic and can be implanted proximal to the affected tissue, bypassing the blood brain barrier, which is impermeable to many agents. Whilst these therapies are not yet widely available in the clinic, promising results have been obtained in several advanced clinical trials and further developmental work is currently underway. This review specifically examines the development of encapsulated cell therapies as treatments for neurological and sensory diseases and evaluates the challenges that are yet to be overcome before they can be made available for clinical use.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22285549     DOI: 10.1016/j.jconrel.2012.01.021

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  7 in total

1.  Chronic neurotrophin delivery promotes ectopic neurite growth from the spiral ganglion of deafened cochleae without compromising the spatial selectivity of cochlear implants.

Authors:  Thomas G Landry; James B Fallon; Andrew K Wise; Robert K Shepherd
Journal:  J Comp Neurol       Date:  2013-08-15       Impact factor: 3.215

2.  Optogenerapy: When bio-electronic implant enters the modern syringe era.

Authors:  Fanny Michel; Marc Folcher
Journal:  Porto Biomed J       Date:  2017-07-29

3.  Sizes and Sufficient Quantities of MSC Microspheres for Intrathecal Injection to Modulate Inflammation in Spinal Cord Injury.

Authors:  Suneel Kumar; Joanne Babiarz; Sayantani Basak; Jae Hwan Kim; Jeffrey Barminko; Andrea Gray; Parry Mendapara; Rene Schloss; Martin L Yarmush; Martin Grumet
Journal:  Nano Life       Date:  2015-12

4.  Improved Auditory Nerve Survival with Nanoengineered Supraparticles for Neurotrophin Delivery into the Deafened Cochlea.

Authors:  Andrew K Wise; Justin Tan; Yajun Wang; Frank Caruso; Robert K Shepherd
Journal:  PLoS One       Date:  2016-10-27       Impact factor: 3.240

5.  An alginate-based encapsulation system for delivery of therapeutic cells to the CNS.

Authors:  Despoina Eleftheriadou; Rachael E Evans; Emily Atkinson; Ahmed Abdalla; Francesca K H Gavins; Ashleigh S Boyd; Gareth R Williams; Jonathan C Knowles; Victoria H Roberton; James B Phillips
Journal:  RSC Adv       Date:  2022-02-01       Impact factor: 3.361

Review 6.  Carriers in cell-based therapies for neurological disorders.

Authors:  Francisca S Y Wong; Barbara P Chan; Amy C Y Lo
Journal:  Int J Mol Sci       Date:  2014-06-13       Impact factor: 6.208

Review 7.  Cell microencapsulation with synthetic polymers.

Authors:  Ronke M Olabisi
Journal:  J Biomed Mater Res A       Date:  2014-08-18       Impact factor: 4.396

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.